Characterization of Gaucher disease bone marrow mesenchymal stromal cells reveals an altered inflammatory secretome

Blood

Volumn 114, Issue 15, 2009, Pages 3181-3190

  Campeau, Philippe M ^a,b   Rafei, Moutih ^a   Boivin, Marie Noëlle ^a   Sun, Ying ^c   Grabowski, Gregory A ^c   Galipeau, Jacques ^a,b,d  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CONDURITOL B EPOXIDE; CYCLOOXYGENASE 2; EPOXIDE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMIGLUCERASE; INTERLEUKIN 8; LACTOSYLCERAMIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; SPHINGOSINE 1 PHOSPHATE; TRANSCRIPTOME; UNCLASSIFIED DRUG; AUTACOID; CCL2 PROTEIN, HUMAN; CONDURITOL EPOXIDE; DRUG DERIVATIVE; ENZYME INHIBITOR; IL8 PROTEIN, HUMAN; INOSITOL; PTGS2 PROTEIN, HUMAN;

ADIPOCYTE; ADULT; ANIMAL CELL; ARTICLE; BONE DISEASE; BONE MARROW; CELL DIFFERENTIATION; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; INFLAMMATION; LYSOSOME; MESENCHYME CELL; MOUSE; NONHUMAN; OSTEOCYTE; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TRANSCRIPTOMICS; UPREGULATION; AMINO ACID SUBSTITUTION; BIOSYNTHESIS; BONE MARROW CELL; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MALE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PATHOLOGY; SECRETION;

ADIPOCYTES; AMINO ACID SUBSTITUTION; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; CHEMOKINE CCL2; CHOLESTEROL; CYCLOOXYGENASE 2; DINOPROSTONE; ENZYME INHIBITORS; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; INFLAMMATION MEDIATORS; INOSITOL; INTERLEUKIN-8; LYSOSOMES; MALE; MIDDLE AGED; MUTATION, MISSENSE; OSTEOCYTES; STROMAL CELLS; UP-REGULATION;

EID: 70350459562     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-205708     Document Type: Article

References (53)

1. Grabowski GA, Beutler E. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2009.
2. Yoshino M, Watanabe Y, Tokunaga Y, et al. Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease. Pediatr Int. 2007;49(6):959-965. (Pubitemid 350197159)
3. van Breemen MJ, de Fost M, Voerman JSA, et al. Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta. 2007;1772(7):788-796. (Pubitemid 46891215)
4. de Fost M, Out TA, de Wilde FA, et al. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol. 2008;87(6):439-449.
5. Boven LA, van Meurs M, Boot RG, et al. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol. 2004;122(3):359-369.
6. Pastores GM, Meere PA. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr Opin Rheumatol. 2005;17(1):70-78.
7. Barak V, Acker M, Nisman B, et al. Cytokines in Gaucher's disease. Eur Cytokine Netw. 1999;10(2):205-210.
8. Moran MT, Schofield JP, Hayman AR, Shi GP, Young E, Cox TM. Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood. 2000;96(5):1969-1978. (Pubitemid 30662113)
9. Hughes DA, Reed MC, Baker RJ, et al. Enhanced differentiation of osteoclasts from circulating mononuclear precursors in patients with Gaucher disease. Acta Paediatrica. 2007;96:106-106
10. Fuller M, Rozaklis T, Lovejoy M, Zarrinkalam K, Hopwood JJ, Meikle PJ. Glucosylceramide accumulation is not confined to the lysosome in fibroblasts from patients with Gaucher disease. Mol Genet Metab. 2008;93(4):437-443.
11. Hein LK, Meikle PJ, Hopwood JJ, Fuller M. Secondary sphingolipid accumulation in a macrophage model of Gaucher disease. Mol Genet Metab. 2007;92(4):336-345. (Pubitemid 350117716)
12. Hein LK, Duplock S, Hopwood JJ, Fuller M. Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res. 2008;4(8):1725-1734.
13. Simons K, Gruenberg J. Jamming the endosomal system: lipid rafts and lysosomal storage diseases. Trends Cell Biol. 2000;10(11):459-462. (Pubitemid 30767757)
14. Cox TM. Future perspectives for glycolipid research in medicine. Philos Trans R Soc Lond B Biol Sci. 2003;358(1433):967-973. (Pubitemid 36639722)
15. Futerman AH. Cellular pathology in Gaucher disease. In: Futerman AH, Zimran A, eds. Gaucher Disease. London, United Kingdom: CRC/Taylor & Francis; 2006:97-109.
16. Wu YP, Mizugishi K, Bektas M, Sandhoff R, Proia RL. Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. Hum Mol Genet. 2008;17(15):2257-2264.
17. Lloyd-Evans E, Morgan AJ, He X, et al. Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. Nat Med. 2008;14(11):1247-1255.
18. Stagg J, Galipeau J. Immune plasticity of bone marrow-derived mesenchymal stromal cells. Handb Exp Pharmacol. 2007;(180):45-66.
19. Phinney DG. Building a consensus regarding the nature and origin of mesenchymal stem cells. J Cell Biochem Suppl. 2002;38:7-12.
20. Zhou S, Greenberger JS, Epperly MW, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008;7(3):335-343. (Pubitemid 351663902)
21. Murphy JM, Dixon K, Beck S, Fabian D, Feldman A, Barry F. Reduced chondrogenic and adipogenic activity of mesenchymal stem cells from patients with advanced osteoarthritis. Arthritis Rheum. 2002;46(3):704-713. (Pubitemid 34218142)
22. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood. 2006;107(6):2570-2577. (Pubitemid 43348704)
23. Wenger DA, Williams C. Screening for lysosomal disorders. In: Hommes FA, ed. Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual. Hoboken, NJ: Wiley-Liss; 1991:587-617.
24. Squillaro T, Hayek G, Farina E, Cipollaro M, Renieri A, Galderisi U. A case report: bone marrow mesenchymal stem cells from a rett syndrome patient are prone to senescence and show a lower degree of apoptosis. J Cell Biochem. 2008;103(6):1877-1885.
25. Singh RD, Marks DL, Pagano RE. Using fluorescent sphingolipid analogs to study intracellular lipid trafficking. Current Protocols in Cell Biology. Hoboken, NJ: Wiley; 2007:24.1.1-24.1.19.
26. Eliopoulos N, Gagnon RF, Francois M, Galipeau J. Erythropoietin delivery by genetically engineered bone marrow stromal cells for correction of anemia in mice with chronic renal failure. J Am Soc Nephrol. 2006;17(6):1576-1584. (Pubitemid 43794660)
27. Deganuto M, Pittis MG, Pines A, et al. Altered intracellular redox status in Gaucher disease fibroblasts and impairment of adaptive response against oxidative stress. J Cell Physiol. 2007;212(1):223-235. (Pubitemid 46867605)
28. Pasmanik-Chor M, Madar-Shapiro L, Stein EO, Aerts H, Gatt S, Horowitz M. Expression of mutated glucocerebrosidase alleles in human cells. Hum Mol Genet. 1997;6(6):887-895. (Pubitemid 27239073)
29. Amaral O, Marcao A, Sa Miranda M, Desnick RJ, Grace ME. Gaucher disease: expression and characterization of mild and severe acid beta-glucosidase mutations in Portuguese type 1 patients. Eur J Hum Genet. 2000;8(2):95-9102. (Pubitemid 30168888)
30. Sillence DJ, Puri V, Marks DL, et al. Glucosylceramide modulates membrane traffic along the endocytic pathway. J Lipid Res. 2002;4(11):1837-1845. (Pubitemid 35315801)
31. Chen CS, Patterson MC, Wheatley CL, O'Brien JF, Pagano RE. Broad screening test for sphingolipid-storage diseases. Lancet. 1999;354(9182):901- 905.
32. Sun Y, Jia L, Williams MT, et al. Temporal gene expression profiling reveals CEBPD as a candidate regulator of brain disease in prosaposin deficient mice. BMC Neurosci. 2008;9:76.
33. Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SRJ, Morrison NA. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NF{kappa}B ligand for bone resorption. J Biol Chem. 2006;281(2):1274-1285.
34. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid hormone stimulates osteoblastic expression of MCP-1 to recruit and increase the fusion of pre/osteoclasts. J Biol Chem. 2007;282(45):33098-33106. (Pubitemid 350159306)
35. Rollins BJ. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. Cancer Cells. 1991;3(12):517-524.
36. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-598.
37. Frade JM, Mellado M, del Real G, Gutierrez-Ramos JC, Lind P, Martinez-A C. Characterization of the CCR2 chemokine receptor: functional CCR2 receptor expression in B cells. J Immunol. 1997;159(11):5576-5584. (Pubitemid 127470087)
38. Vande Broek I, Asosingh K, Vanderkerken K, Straetmans N, Van Camp B, Van Riet I. Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1, -2 and -3. Br J Cancer. 2003;88(6):855-862. (Pubitemid 36520872)
39. Pellegrino A, Ria R, Di Pietro G, et al. Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol. 2005;129(2):248-256. (Pubitemid 40562446)
40. Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res. 2006;134(1):44-51. (Pubitemid 43866829)
41. Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33(1):28-37. (Pubitemid 36952685)
42. Kaneko H, Mehrotra M, Alander C, Lerner U, Pilbeam C, Raisz L. Effects of prostaglandin E2 and lipopolysaccharide on osteoclastogenesis in RAW 264.7 cells. Prostaglandins Leukot Essent Fatty Acids. 2007;77(3-4):181-186. (Pubitemid 350138420)
43. Otsuki T, Yata K, Sakaguchi H, et al. IL-10 in myeloma cells. Leuk Lymphoma. 2002;43(5):969-974.
44. Nemeth K, Leelahavanichkul A, Yuen PST, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med. 2009;15(1):42-49.
45. Adachi M, Volk BW. Gaucher disease in mice induced by conduritol-B-epoxide: morphologic features. Arch Pathol Lab Med. 1977;101(5):255-259. (Pubitemid 8191403)
46. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397-407.
47. Kanfer JN, Legler G, Sullivan J, Raghavan SS, Mumford RA. The Gaucher mouse. Biochem Biophys Res Commun. 1975;67(1):85-90.
48. Hayman AR, Jones SJ, Boyde A, et al. Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development. 1996;122(10):3151-3162. (Pubitemid 26371980)
49. Mosig RA, Dowling O, DiFeo A, et al. Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet. 2007;16(9):1113-1123. (Pubitemid 47062731)
50. Schindelmeiser J, Radzun HJ, Munstermann D. Tartrate-resistant, purple acid phosphatase in Gaucher cells of the spleen. Immuno- and cytochemical analysis. Pathol Res Pract. 1991;187(2-3):209-213.
51. van Breemen MJ, Aerts JMFG, Sprenger RR, Speijer D. Potential artefacts in proteome analysis of plasma of Gaucher patients due to protease abnormalities. Clin Chim Acta. 2008;396(1-2):26-32.
52. Sahu SK, Gummadi SN, Manoj N, Aradhyam GK. Phospholipid scramblases: an overview. Arch Biochem Biophys. 2007;462(1):103-114.
53. Schroeder F, Atshaves BP, McIntosh AL, et al. Sterol carrier protein-2: new roles in regulating lipid rafts and signaling. Biochim Biophys Acta. 2007;1771(6):700-718. (Pubitemid 46856895)